Eli Lilly and Company (LLY) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Eli Lilly And Company.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.000 -- 00:00:05.140 Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q2 2025 earnings 00:00:05.140 -- 00:00:09.040 conference call. At this time, all participants are on a listen-only mode. 00:00:09.040 -- 00:00:12.920 Later, we will be conducting a question and answer session and instructions will be given 00:00:12.920 -- 00:00:18.000 at that time. Should you request assistance during the call, please press star then 00:00:18.000 -- 00:00:20.960 zero and an operator will assist you offline. 00:00:20.960 -- 00:00:25.340 I would now like to turn the conference over to your host, Mike Zapar, Senior Vice President 00:00:25.340 -- 00:00:28.820 of Investor Relations. Please go ahead. 00:00:28.820 -- 00:00:33.840 Good morning. Thank you for joining us for E9 Lilly and Company's Q2 2025 earnings 00:00:33.840 -- 00:00:38.040 call. I'm Mike Zapar, Senior Vice President of Investor Relations. 00:00:38.040 -- 00:00:42.880 Joining me on today's call are Dave Ricks, Lilly's Chair and CEO, Lucas Mondarse, Chief 00:00:42.880 -- 00:00:47.740 Financial Officer, Dr. Dan Skowronski, Chief Scientific Officer and President of Lilly 00:00:47.740 -- 00:00:49.160 Immunology, 00:00:49.160 -- 00:00:51.940 Anne White, President of Lilly Neuroscience, 00:00:51.940 -- 00:00:57.140 Ilya Yufa, President of Lilly USA and Global Customer Capabilities, Jake Van Arden, 00:00:57.140 -- 00:01:02.040 President of Lilly Oncology, Patrick Janssen, President of Lilly International and Ken 00:01:02.040 -- 00:01:06.420 Custer, newly appointed President of Lilly Cardiometabolic Health. 00:01:06.420 -- 00:01:10.320 We're also joined by Mark Heumann, Susan Hedgeland and Wai Wong of the Investor Relations 00:01:10.320 -- 00:01:14.900 team. During this call, we anticipate ma...